Clinical Trial

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This research study is studying a combination of two targeted therapies as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The drugs involved in this study are: * Osimertinib (Tagrisso) * Selumetinib
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06-30 -> 2027-06-30 2026-08-12
minor Completion pushed: 2026-12-30 -> 2027-12-30 2026-08-12
Trial Details
NCT Number NCT03392246
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: National Comprehensive Cancer Network
Conditions Non-small Cell Lung Cancer
Enrollment 25 participants
Start Date 2018-01-31
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-11